)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Genfit
Genfit (GNFT) investor relations material
Genfit Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary28 Sep, 2026
Executive summary
Achieved strong commercial performance for IqirvoⓇ (elafibranor) in PBC, with first-year net sales of $208M and a €20M milestone payment received one year ahead of plan.
Ipsen increased estimated peak annual sales for IqirvoⓇ in PBC from €500M to €1B, reflecting robust market uptake and momentum.
Medicare reimbursement for NASHnextⓇ, a MASH diagnostic, became effective in August 2026, supporting broader adoption and future diagnostic revenue.
Cash and cash equivalents reached €113.8M as of June 30, 2026, expected to fund operations beyond 2028.
Advanced R&D pipeline with three clinical-stage assets (nitazoxanide, nangibotide, GNS561), all progressing to Phase 2 in 2H26, with readouts expected in 2027.
Financial highlights
Revenue and other income for H1 2026 totaled €25.0M, down from €35.7M in H1 2025, mainly due to lower milestone revenue.
Royalty revenue increased to €21.0M (H1 2026) from €6.9M (H1 2025), while milestone revenue dropped to zero from €26.6M.
Net loss widened to €26.1M in H1 2026 from €10.0M in H1 2025, driven by higher fair value adjustments on royalty financing.
Cash and cash equivalents rose to €113.8M as of June 30, 2026, from €101.1M at year-end 2025.
Operating expenses decreased to €33.8M in H1 2026 from €35.6M in H1 2025.
Outlook and guidance
Existing cash and equivalents expected to fund operations beyond 2028, assuming continued milestone and royalty inflows.
Focus remains on advancing three Phase 2 clinical trials (nangibotide, nitazoxanide, GNS561) and expanding NIST diagnostic adoption.
Anticipates further milestone and royalty payments from Ipsen as IqirvoⓇ sales grow and new indications progress.
Broader reimbursement and IVD launch for NIS™ technology could accelerate adoption and revenue growth.
Phase 2 clinical trial readouts for nangibotide, nitazoxanide, and GNS561 expected in 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Genfit
- Commercial success in PBC, diagnostic advances in MASH, and a strong pipeline drive future growth.GNFT
H.C. Wainwright 28th Annual Global Investment Conference presentation - Cash position strengthened by royalty financing, with Q1 revenue growth from IqirvoⓇ royalties.GNFTQ1 2025
- NIS2+ enables scalable MASH diagnosis and monitoring, unlocking a $1.5B market opportunity.GNFTKOL event
- Robust pipeline and partnerships drive growth in rare liver diseases and diagnostics.GNFTCorporate presentation
- Q1 2026 revenue up 243% to €9.6M, with strong cash and major clinical milestones reached.GNFTQ1 2026 TU
- Expanding rare liver disease portfolio and diagnostics drive financial and clinical momentum.GNFTInvestor presentation
- Net loss of €10.0 million in H1 2025, cash runway extended beyond 2028 after VS-01 discontinuation.GNFTQ2 2025
- FDA approval and U.S. launch of Iqirvo® drove record profit, revenue, and strong cash outlook.GNFTQ2 2024
- GENFIT achieved profitability and secured major financing, fueling pipeline progress and commercial growth.GNFTQ4 2024
Next Genfit earnings date
Q3 2026 TU5 Nov, 2026
Genfit
Next Genfit earnings date
Q3 2026 TU5 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage